Modulation of subventricular zone neurogenesis by cannabinoid type 2 receptor and “exercise-regulated” neurotrophic factors
-
1
Institute of Pharmacology and Neurosciences, Faculty of Medicine, University of Lisbon, Portugal
-
2
Institute of Molecular Medicine, Faculty of Medicine, University of Lisbon, Portugal
-
3
Department of Life Sciences, Faculty of Sciences and Technology, University of Coimbra, Portugal
Neurogenesis is a highly complex process by which new functional neurons are generated through the differentiation of neural stem cells (NSCs). Physical exercise has been indicated as an enhancer of hippocampal neurogenesis and as a rescuer of defective SVZ neurogenesis. Endocannabinoids activate primarily type 1 and 2 receptors (CB1R and CB2R) and have been shown to play crucial roles in different neurogenic stages. Significantly, in vitro data from our group sheds light on an interaction between CB2R and brain-derived neurotrophic factor (BDNF) signaling in SVZ neurogenesis, being BDNF one of the most important “exercise-regulated” neurotrophic factors. Interestingly, evidence shows that endocannabinoids, via CB1R, are required for exercise to increase proliferation of NSCs cells within the DG. However, the combination of CB2R modulation with exercise has never been studied concerning SVZ neurogenesis.
Therefore, the current project aims to study whether “exercise-regulated” neurotrophic factors combined with CB2R modulation play an impactful role on SVZ neurogenesis.
Hence, the effects mediated by CB2R modulation in different neurogenic features was evaluated in vitro, using P1-3 mice SVZ neurospheres that were pharmacological treated with CB2R agonist HU-308, CB2R antagonist AM630 and “exercise-regulated” neurotrophic factors namely BDNF, vascular endothelial growth factor (VEGF) and insulin-like growth factor 1 (IGF-1). A concentration-response curve for BDNF, VEGF, IGF-1 (10, 30 and 100 ng/ml), HU-308 (100, 300 nM and 1 μM) and AM630 (300 nM, 1 and 10 μM) was performed. Cell proliferation was analyzed by BrdU staining and cell death by propidium iodide staining.
Preliminary results show that pharmacological treatments did not increase cell death or change cell proliferation, except for IGF-1 (100 ng/ml) which showed a tendency for an increase in cell proliferation (N=1-3).
This study will help shed light in the potential synergism between physical exercise and endocannabinoid signaling in regulating adult SVZ neurogenesis. This modulation may have an impactful role on SVZ neurogenesis which might be relevant for future brain repair strategies.
Keywords:
Neurogenesis,
SVZ = subventricular zone,
Endocannabinoids (eCBs),
CB2R,
Physical exercice
Conference:
XVI Meeting of the Portuguese Society for Neuroscience (SPN2019), Lisboa, Portugal, 30 May - 1 Jun, 2019.
Presentation Type:
Poster presentation
Topic:
Neurodevelopment / Regeneration
Citation:
Moreira
JB,
Rodrigues
RS,
Lourenço
DM,
Sebastião
AM and
Xapelli
S
(2019). Modulation of subventricular zone neurogenesis by cannabinoid type 2 receptor and “exercise-regulated” neurotrophic factors.
Front. Cell. Neurosci.
Conference Abstract:
XVI Meeting of the Portuguese Society for Neuroscience (SPN2019).
doi: 10.3389/conf.fncel.2019.01.00036
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
26 Feb 2019;
Published Online:
27 Sep 2019.
*
Correspondence:
Dr. Sara Xapelli, Institute of Pharmacology and Neurosciences, Faculty of Medicine, University of Lisbon, Lisbon, 1649-028, Portugal, sxapelli@medicina.ulisboa.pt